Cargando…
612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries
BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substit...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810906/ http://dx.doi.org/10.1093/ofid/ofz360.681 |
_version_ | 1783462349587349504 |
---|---|
author | Mojica, Maria F Rios, Rafael De La Cadena, Elsa Correa, Adriana Diaz, Lorena Millan, Lina V Hernandez, Angie K Reyes, Jinnethe Hernández-Gómez, Cristhian Radice, Marcela A Castañeda-Méndez, Paulo Jaime-Villalón, Diego A Gales, Ana C Munita, Jose M López, Catalina Rojas Rojas, Monica Maria Virginia Villegas, Maria |
author_facet | Mojica, Maria F Rios, Rafael De La Cadena, Elsa Correa, Adriana Diaz, Lorena Millan, Lina V Hernandez, Angie K Reyes, Jinnethe Hernández-Gómez, Cristhian Radice, Marcela A Castañeda-Méndez, Paulo Jaime-Villalón, Diego A Gales, Ana C Munita, Jose M López, Catalina Rojas Rojas, Monica Maria Virginia Villegas, Maria |
author_sort | Mojica, Maria F |
collection | PubMed |
description | BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substitutions in the Pseudomonal-derived cephalosporinase (PDC), in AmpR, and in some ESBLs, are the most commonly described. The aim of this study was to identify the molecular mechanisms responsible for the in vitro non-susceptibility (NS) to C/T in a group of clinical Pae strains from Latin America. METHODS: Clinical Pae isolates (n = 508) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to C/T were determined by standard broth microdilution and interpreted according to CLSI M100 S28 breakpoints. Production of carbapenemases in Pae isolates displaying NS to C/T was assessed by carbaNP® followed by PCR to detect blaKPC, blaNDM-1, blaVIM and blaIMP. Illumina whole-genome sequencing (WGS) was performed for isolates in which NS to C/T was not mediated by carbapenemases. The presence of mutations in PDC, AmpR, oprD and dacB as compared with PAO1, was evaluated. RESULTS: According to the CLSI breakpoints, 162/508 (32%) Pae isolates demonstrated NS to C/T. Due to the absence of growth, only 151/162 were further processed. Table 1 summarizes the results obtained by carbaNP®, PCR and WGS performed on these isolates. In 53% of the isolates, NS to C/T was explained by the production of at least one carbapenemase, KPC or VIM. WGS revealed that in addition to substitutions in PDC and AmpR, some isolates carried mutations in oprD and dacB (encoding PBP4) genes. The molecular mechanism of resistance in 4/56 isolates is yet to be determined. CONCLUSION: Carbapenemase production is the most common mechanism of resistance to C/T detected in this study. VIM and KPC were detected in equal proportions, while none of the isolates was found to carry IMP or NDM. Further studies are warranted to establish the role of the novel substitutions found in PDC and AmpR, as well as the degree to which the mutations found in oprD and dacB contribute to the NS phenotype in some isolates. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68109062019-10-28 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries Mojica, Maria F Rios, Rafael De La Cadena, Elsa Correa, Adriana Diaz, Lorena Millan, Lina V Hernandez, Angie K Reyes, Jinnethe Hernández-Gómez, Cristhian Radice, Marcela A Castañeda-Méndez, Paulo Jaime-Villalón, Diego A Gales, Ana C Munita, Jose M López, Catalina Rojas Rojas, Monica Maria Virginia Villegas, Maria Open Forum Infect Dis Abstracts BACKGROUND: Ceftolozane–tazobactam (C/T) is a combination of an antipseudomonal cephalosporin with a known β-lactamase inhibitor, with a potent in vitro activity against P. aeruginosa (Pae), without activity against carbapenemases. Among the mechanisms of resistance to C/T that have emerged, substitutions in the Pseudomonal-derived cephalosporinase (PDC), in AmpR, and in some ESBLs, are the most commonly described. The aim of this study was to identify the molecular mechanisms responsible for the in vitro non-susceptibility (NS) to C/T in a group of clinical Pae strains from Latin America. METHODS: Clinical Pae isolates (n = 508) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to C/T were determined by standard broth microdilution and interpreted according to CLSI M100 S28 breakpoints. Production of carbapenemases in Pae isolates displaying NS to C/T was assessed by carbaNP® followed by PCR to detect blaKPC, blaNDM-1, blaVIM and blaIMP. Illumina whole-genome sequencing (WGS) was performed for isolates in which NS to C/T was not mediated by carbapenemases. The presence of mutations in PDC, AmpR, oprD and dacB as compared with PAO1, was evaluated. RESULTS: According to the CLSI breakpoints, 162/508 (32%) Pae isolates demonstrated NS to C/T. Due to the absence of growth, only 151/162 were further processed. Table 1 summarizes the results obtained by carbaNP®, PCR and WGS performed on these isolates. In 53% of the isolates, NS to C/T was explained by the production of at least one carbapenemase, KPC or VIM. WGS revealed that in addition to substitutions in PDC and AmpR, some isolates carried mutations in oprD and dacB (encoding PBP4) genes. The molecular mechanism of resistance in 4/56 isolates is yet to be determined. CONCLUSION: Carbapenemase production is the most common mechanism of resistance to C/T detected in this study. VIM and KPC were detected in equal proportions, while none of the isolates was found to carry IMP or NDM. Further studies are warranted to establish the role of the novel substitutions found in PDC and AmpR, as well as the degree to which the mutations found in oprD and dacB contribute to the NS phenotype in some isolates. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810906/ http://dx.doi.org/10.1093/ofid/ofz360.681 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Mojica, Maria F Rios, Rafael De La Cadena, Elsa Correa, Adriana Diaz, Lorena Millan, Lina V Hernandez, Angie K Reyes, Jinnethe Hernández-Gómez, Cristhian Radice, Marcela A Castañeda-Méndez, Paulo Jaime-Villalón, Diego A Gales, Ana C Munita, Jose M López, Catalina Rojas Rojas, Monica Maria Virginia Villegas, Maria 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title | 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title_full | 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title_fullStr | 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title_full_unstemmed | 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title_short | 612. Molecular Mechanisms Leading to Ceftolozane–Tazobactam Resistance in Clinical Isolates of Pseudomonas aeruginosa from Five Latin American Countries |
title_sort | 612. molecular mechanisms leading to ceftolozane–tazobactam resistance in clinical isolates of pseudomonas aeruginosa from five latin american countries |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810906/ http://dx.doi.org/10.1093/ofid/ofz360.681 |
work_keys_str_mv | AT mojicamariaf 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT riosrafael 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT delacadenaelsa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT correaadriana 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT diazlorena 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT millanlinav 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT hernandezangiek 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT reyesjinnethe 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT hernandezgomezcristhian 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT radicemarcelaa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT castanedamendezpaulo 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT jaimevillalondiegoa 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT galesanac 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT munitajosem 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT lopezcatalina 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT rojasrojasmonicamaria 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries AT virginiavillegasmaria 612molecularmechanismsleadingtoceftolozanetazobactamresistanceinclinicalisolatesofpseudomonasaeruginosafromfivelatinamericancountries |